WERA Drug Patent Profile
When do Wera patents expire, and what generic alternatives are available?
Wera is a drug marketed by Novast Labs Ltd and is included in one NDA.
The generic ingredient in WERA is ethinyl estradiol; norethindrone. There is one drug master file entry for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for WERA?
- What are the global sales for WERA?
- What is Average Wholesale Price for WERA?
Summary for WERA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 3 |
| Drug Prices: | Drug price information for WERA |
| Drug Sales Revenues: | Drug sales revenues for WERA |
| DailyMed Link: | WERA at DailyMed |
US Patents and Regulatory Information for WERA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novast Labs Ltd | WERA | ethinyl estradiol; norethindrone | TABLET;ORAL-28 | 091204-001 | Mar 27, 2012 | AB | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
